Development and Validation of a Nomogram for the Prediction of Unfavorable Treatment Outcome Among Multi-Drug Resistant Tuberculosis Patients in North West Ethiopia: An Application of Prediction Modelling

References

• World Health Organization. Global Tuberculosis Report 2020. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO. Available from: https://www.who.int/publications/i/item/9789240013131. Accessed February 5, 2021.
   Google Scholar
• Global Tuberculosis Report. Advocacy toolkit; 2020.
   Google Scholar
• Stop TB Partnership. High Burden Countries for Tuberculosis. Global Health Campus. Geneva, Switzerland 2021. Available from. https://www.stoptb.org/securing-quality-tb-care-all/high-burden-countries-tuberculosis. Accessed on February 5, 2021.
   Google Scholar
• World Health Oraganization. Global Tuberculosis Report 2016. Geneva: World Health Organization; 2016. Available from: https://apps.who.int/iris/bitstream/handle/10665/250441/9789241565394-eng.pdf?sequence=1. Accessed February 5, 2021.
   Google Scholar
• (FDRE-MH), F.D.R.o.E.M.o.H. National strategic plan tuberculosis and leprosy control 2006–2013 EC (2013/14 – 2020) with update – for 2010; 2017.
   Google Scholar
• Alemu A, Bitew ZW, Worku T. Poor treatment outcome and its predictors among drug-resistant tuberculosis patients in Ethiopia: a systematic review and meta-analysis. Int J Infect Dis. 2020;98:420–439. doi:10.1016/j.ijid.2020.05.087
   PubMed Web of Science ®Google Scholar
• Baye A, Sarhie WD, Endalew B. Treatment outcomes of multi-drug-resistant tuberculosis and its determinants in Boru Meda hospital, Northeast Ethiopia. J Infect Dis Ther. 2018;6(350):1–5. doi:10.4172/2332-0877.1000350
   Google Scholar
• Bekele TA, Aynalem GA, Berhe TT. Multi-drug resistant tuberculosis treatment outcome and associated factors in Addis Ababa, Ethiopia: a retrospective cross-sectional study; 2020.
   Google Scholar
• Girum T, Tariku Y, Dessu S. Survival status and treatment outcome of multidrug resistant tuberculosis (MDR-TB) among patients treated in treatment initiation centers (TIC) in South Ethiopia: a retrospective cohort study. Ann Med Health Sci Res. 2017;7(5):1.
   Web of Science ®Google Scholar
• Woldeyohannes D, Assefa T, Aman R, et al. Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia. PLoS One. 2019;14(10):e0224025. doi:10.1371/journal.pone.0224025
   Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report 2018. Geneva: World Health Organization. Licence: CC BY-NC-SA 3.0 IGO; 2018.
   Google Scholar
• World Health Organization. Ethiopia launched new guideline for reaching missed tuberculosis cases; 2018.
   Google Scholar
• Arroyo LH, Ramos ACV. Predictive model of unfavorable outcomes for multidrug-resistant tuberculosis. Revista de Saúde Pública. 2019;53:77.
   Web of Science ®Google Scholar
• Butov D, Lange C, Heyckendorf J, et al. Multidrug-resistant tuberculosis in the Kharkiv Region, Ukraine. Medicine. 2020;24(5):485–491.
   Google Scholar
• Elmi OS, Hasan H, Abdullah S, et al. Treatment outcomes of patients with Multidrug-Resistant Tuberculosis (MDR- TB) compared with Non-MDR-TB infections in Peninsular Malaysia. Malays J Med Sci. 2016;23(4):17–25.
   Google Scholar
• Janmeja AK, Aggarwal D, Dhillon R. Factors predicting treatment success in multi-drug resistant tuberculosis patients treated under programmatic conditions. Indian J Tuberc. 2018;65(2):135–139. doi:10.1016/j.ijtb.2017.12.015
   Google Scholar
• Khaliaukin A, Kumar AMV, Skrahina A, et al. Poor treatment outcomes among multidrug-resistant tuberculosis patients in Gomel Region, Republic of Belarus. Public Health Action. 2014;4(Suppl 2):S24–S28. doi:10.5588/pha.14.0042
   PubMedGoogle Scholar
• Mohd Shariff N, Shah SA, Kamaludin F. Predictors of death among drug-resistant tuberculosis patients in Kuala Lumpur, Malaysia: a retrospective cohort study from 2009 to 2013. J Glob Antimicrob Resist. 2016;6:102–107. doi:10.1016/j.jgar.2016.04.005
   Web of Science ®Google Scholar
• Parmar MM, Sachdeva KS, Dewan PK, et al. Unacceptable treatment outcomes and associated factors among India’s initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007–2011): evidence leading to policy enhancement. PLoS One. 2018;13(4):e0193903. doi:10.1371/journal.pone.0193903
   Web of Science ®Google Scholar
• Tang S, Tan S, Yao L, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One. 2013;8(12):e82943. doi:10.1371/journal.pone.0082943
   PubMed Web of Science ®Google Scholar
• Tobón Á, Rueda J, Cáceres DH, et al. Adverse treatment outcomes in multidrug resistant tuberculosis go beyond the microbe-drug interaction: results of a multiple correspondence analysis. Biomedica. 2020;40(4):616–625. doi:10.7705/biomedica.5072
   Web of Science ®Google Scholar
• Van LH, Phu PT, Vinh DN, et al. Risk factors for poor treatment outcomes of 2266 multidrug-resistant tuberculosis cases in Ho Chi Minh City: a retrospective study. BMC Infect Dis. 2020;20(1):164. doi:10.1186/s12879-020-4887-1
   PubMed Web of Science ®Google Scholar
• Zhang L, Meng Q, Chen S, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009–2013. Clin Microbiol Infect. 2018;24(4):381–388. doi:10.1016/j.cmi.2017.07.008
   PubMed Web of Science ®Google Scholar
• Li Q, Shi CX, Lu M, et al. Treatment outcomes of multidrug-resistant tuberculosis in Hangzhou, China, 2011 to 2015. Medicine. 2020;99(30):e21296. doi:10.1097/MD.0000000000021296
   Web of Science ®Google Scholar
• Aibana O, Bachmaha M, Krasiuk V, et al. Risk factors for poor multidrug-resistant tuberculosis treatment outcomes in Kyiv Oblast, Ukraine. BMC Infect Dis. 2017;17(1):129. doi:10.1186/s12879-017-2230-2
   Web of Science ®Google Scholar
• Huerga H, Bastard M, Kamene M, et al. Outcomes from the first multidrug-resistant tuberculosis programme in Kenya. Int J Tuberc Lung Dis. 2017;21(3):314–319. doi:10.5588/ijtld.16.0661
   Web of Science ®Google Scholar
• Nguyen NV. Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance. Trop Med Infect Dis. 2015;19(9):1109–1114.
   Google Scholar
• van Altena R, de Vries G, Haar CH, et al. Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000–2009. Int J Tuberc Lung Dis. 2015;19(4):406–412. doi:10.5588/ijtld.14.0838
   PubMed Web of Science ®Google Scholar
• Verdecchia M, Keus K, Blankley S. Model of care and risk factors for poor outcomes in patients on multi-drug resistant tuberculosis treatment at two facilities in Eswatini (formerly Swaziland), 2011–2013. PLoS One. 2018;13(10):e0205601. doi:10.1371/journal.pone.0205601
   Web of Science ®Google Scholar
• Riley RD, Snell KI, Ensor J, et al. Minimum sample size for developing a multivariable prediction model: PART II‐binary and time‐to‐event outcomes. Stat Med. 2019;38(7):1276–1296. doi:10.1002/sim.7992
   PubMed Web of Science ®Google Scholar
• World Health Organization. Definitions and reporting framework for tuberculosis. Geneva, Swizerland; 2013. Available from: https://apps.who.int/iris/bitstream/handle/10665/79199/9789241505345_eng.pdf?sequence=1. Accessed February 6, 2021.
   Google Scholar
• Pavlou M, Ambler G, Seaman SR, et al. How to develop a more accurate risk prediction model when there are few events. BMJ. 2015;351. doi:10.1136/bmj.h3868
   Web of Science ®Google Scholar
• Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for some traditional and novel measures. Epidemiology. 2010;21(1):128. doi:10.1097/EDE.0b013e3181c30fb2
   PubMed Web of Science ®Google Scholar
• Zhou Z-R, Wang -W-W, Li Y, et al. In-depth mining of clinical data: the construction of clinical prediction model with R. Ann Transl Med. 2019;7(23):796. doi:10.21037/atm.2019.08.63
   PubMed Web of Science ®Google Scholar
• Swets JA. Measuring the accuracy of diagnostic systems; 1988.
   Google Scholar
• Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015;350:g7594. doi:10.1136/bmj.g7594
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Cronin AM, Elkin EB, et al. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8(1):1–17. doi:10.1186/1472-6947-8-53
   PubMed Web of Science ®Google Scholar
• Bélard S, Bootsma S, Traoré AN, et al. Tuberculosis treatment outcome and drug resistance in lambarene, Gabon: a prospective cohort study. Am J Trop Med Hyg. 2016;95(2):472–480. doi:10.4269/ajtmh.15-0668
   Web of Science ®Google Scholar
• Leveri TH, Lekule I, Mollel E, et al. Predictors of treatment outcomes among multidrug resistant tuberculosis patients in Tanzania. Tuberc Res Treat. 2019;2019. doi:10.1155/2019/3569018
   Google Scholar
• Phuong N, Nhung NV, Hoa NB, et al. Management and treatment outcomes of patients enrolled in MDR-TB treatment in Viet Nam. Public Health Action. 2016;6(1):25–31. doi:10.5588/pha.15.0068
   Google Scholar
• Kibret KT, Moges Y, Memiah P, et al. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty. 2017;6(1):1–8. doi:10.1186/s40249-016-0214-x
   Web of Science ®Google Scholar
• Nair D, Velayutham B, Kannan T, et al. Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India. Public Health Action. 2017;7(1):32–38. doi:10.5588/pha.16.0055
   Web of Science ®Google Scholar
• Kalandarova L, Tillashaikhov M, Parpieva N, et al. Treatment outcomes and adverse reactions in patients with multidrug-resistant tuberculosis managed by ambulatory or hospitalized care from 2010–2011 in Tashkent, Uzbekistan. Public Health Panorama. 2016;2(1):21–29.
   Google Scholar
• Oliveira O, Gaio R, Correia-Neves M, et al. Evaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000–2016. PLoS One. 2021;16(4):e0250028. doi:10.1371/journal.pone.0250028
   Web of Science ®Google Scholar
• Bhering M, Duarte R, Kritski A, Escobar-Gutiérrez A. Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000–2016. PLoS One. 2019;14(11):e0218299. doi:10.1371/journal.pone.0218299
   PubMed Web of Science ®Google Scholar
• Suryawanshi S, Shewade HD, Nagaraja SB, et al. Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India. Public Health Action. 2017;7(2):116–122. doi:10.5588/pha.17.0013
   PubMed Web of Science ®Google Scholar
• Chaves-Torres NM, Fadul S, Patiño J, et al. Factors associated with unfavorable treatment outcomes in patients with rifampicin-resistant tuberculosis in Colombia 2013–2015: a retrospective cohort study. PLoS One. 2021;16(4):e0249565. doi:10.1371/journal.pone.0249565
   Web of Science ®Google Scholar
• Khachatryan L, Grigoryan R, Dadu A, et al. Factors associated with unfavourable treatment outcomes among people with rifampicin-resistant tuberculosis in Armenia, 2014–2017. Monaldi Arch Chest Dis. 2021;91(1). doi:10.4081/monaldi.2021.1677
   Web of Science ®Google Scholar
• Schnippel K, Ndjeka N, Maartens G, et al. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. Lancet Respir Med. 2018;6(9):699–706. doi:10.1016/S2213-2600(18)30235-2
   PubMed Web of Science ®Google Scholar
• Alene KA, Viney K, McBryde ES, et al. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia. Trop Med Int Health. 2017;22(3):351–362. doi:10.1111/tmi.12826
   PubMed Web of Science ®Google Scholar
• Li D, Ge E, Shen X, et al. Risk factors of treatment outcomes for multi-drug resistant tuberculosis in Shanghai, 2009–2012. Procedia Environ Sci. 2016;36:12–19. doi:10.1016/j.proenv.2016.09.003
   Google Scholar
• Bogale L, Tsegaye T, Abdulkadir M, et al. Unfavorable treatment outcome and its predictors among patients with multidrug-resistance tuberculosis in Southern Ethiopia in 2014 to 2019: a multi-center retrospective follow-up study. Infect Drug Resist. 2021;14:1343. doi:10.2147/IDR.S300814
   PubMed Web of Science ®Google Scholar
• Bhering M, Kritski A. Primary and acquired multidrug-resistant tuberculosis: predictive factors for unfavorable treatment outcomes in Rio de Janeiro, 2000–2016. Revista Panamericana de Salud Pública. 2020;44:1. doi:10.26633/RPSP.2020.178
   Web of Science ®Google Scholar
• Gadallah MA, Mokhtar A, Rady M, et al. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt. J Formos Med Assoc. 2016;115(11):997–1003. doi:10.1016/j.jfma.2015.10.002
   PubMed Web of Science ®Google Scholar
• Samuels JP, Sood A, Campbell JR, et al. Comorbidities and treatment outcomes in multidrug resistant tuberculosis: a systematic review and meta-analysis. Sci Rep. 2018;8(1):1–13. doi:10.1038/s41598-018-23344-z
   Web of Science ®Google Scholar
• Khan I, Ahmad N, Khan S, et al. Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan. J Infect Public Health. 2019;12(6):809–815. doi:10.1016/j.jiph.2019.04.009
   Web of Science ®Google Scholar
• Zhang Y, Wu S, Xia Y, et al. Adverse events associated with treatment of multidrug-resistant tuberculosis in China: an ambispective cohort study. Med Sci Monit. 2017;23:2348. doi:10.12659/MSM.904682
   PubMed Web of Science ®Google Scholar
• Shean K, Streicher E, Pieterson E, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One. 2013;8(5):e63057. doi:10.1371/journal.pone.0063057
   PubMed Web of Science ®Google Scholar
• Harouna S, Ortuno-Gutierrez N, Souleymane MB, et al. Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger. Int J Tuberc Lung Dis. 2019;23(5):625–630. doi:10.5588/ijtld.17.0871
   PubMed Web of Science ®Google Scholar
• Yin J, Wang X, Zhou L, et al. The relationship between social support, treatment interruption and treatment outcome in patients with multidrug‐resistant tuberculosis in China: a mixed‐methods study. Trop Med Int Health. 2018;23(6):668–677. doi:10.1111/tmi.13066
   PubMed Web of Science ®Google Scholar
• Wen S, Yin J, Sun Q. Impacts of social support on the treatment outcomes of drug-resistant tuberculosis: a systematic review and meta-analysis. BMJ open. 2020;10(10):e036985. doi:10.1136/bmjopen-2020-036985
   PubMed Web of Science ®Google Scholar
• Azagba CK. Tuberculosis treatment outcomes using treatment supporters in Ketu South Municipality of Volta Region in Ghana. University of Ghana; 2013.
   Google Scholar
• Abdelbary BE, Garcia-Viveros M, Ramirez-Oropesa H, et al. Predicting treatment failure, death and drug resistance using a computed risk score among newly diagnosed TB patients in Tamaulipas, Mexico. Epidemiol Infect. 2017;145(14):3020–3034. doi:10.1017/S0950268817001911
   PubMed Web of Science ®Google Scholar
• Madan C, Chopra KK, Satyanarayana S, et al. Developing a model to predict unfavourable treatment outcomes in patients with tuberculosis and human immunodeficiency virus co-infection in Delhi, India. PLoS One. 2018;13(10):e0204982. doi:10.1371/journal.pone.0204982
   PubMed Web of Science ®Google Scholar
• World Health Organization. The End TB Strategy. World Health Organization; 2015. Available from: https://www.who.int/tb/strategy/en/. Accessed February 2, 2021.
   Google Scholar
• World Health Organization. Framework for implementing the “End TB Strategy” in the African Region 2016–2020. Geneva: World Health Organization; 2017. Available from: http://apps.who.int/iris. Accessed July 13, 2022.
   Google Scholar